A Randomized, Multicenter, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam Compared to Vehicle in the Treatment of Facial Papulopustular Rosacea (FX2016-11 and 12)
Phase of Trial: Phase III
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Minocycline (Primary)
- Indications Rosacea
- Focus Therapeutic Use
- Sponsors Foamix
- 31 Aug 2017 Planned number of patients changed from 750 to 1500.
- 31 Aug 2017 Planned End Date changed from 22 Aug 2018 to 22 Oct 2018.
- 31 Aug 2017 Planned primary completion date changed from 14 May 2017 to 13 Sep 2018.